CORAL SPRINGS, FL--(Marketwired - December 06, 2013) - Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin®, in the Network Marketing channel is launching their distributor website http://www.mynyloxin.com over the coming weekend. The website will allow for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
"Pain affects more Americans than diabetes, heart disease and cancer combined. According to the Institute of Medicine of The National Academies, chronic pain affects 100 million Americans. Millions suffer from acute or chronic pain and the effects of pain exact a tremendous cost on our country in health care costs, rehabilitation and lost worker productivity, as well as the emotional and financial burden it places on patients and their families," stated Dalton Johnson, CEO of MyNyloxin.com. "MyNyloxin.com is comprised of a group of professional marketers whom have come together on a mission to spread awareness of Nyloxin," he continued. "The new MyNyloxin.com website will improve the lives of people. By providing access to a superior pain relief product that customers need and can trust and by providing an innovative network marketing program which offers a fair and balanced compensation plan for both the average and ambitious MyNyloxin Independent Entrepreneur," he concluded.
In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin® to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. TCN has now created a stand-alone opportunity for distributors under the name MyNyloxin. The launch begins today and will take place throughout the month of December. The launch includes webinars, internet, radio and television advertising.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. The Company recently announced the beginning of marketing efforts by New Vitality for the Direct Response and retail marketing of Nyloxin. New Vitality's first Nyloxin television commercials are scheduled to begin shortly.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The launch of MyNyloxin.com should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.